Squarepoint’s MoonLake Immunotherapeutics MLTX Stock Holding History

Squarepoint’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.66M	Sell	85,147 -25,070	-23%	-$454K	﹤0.01%	2488
2026 Q1	$2.05M	Sell	110,217 -11,423	-9%	-$189K	﹤0.01%	2161
2025 Q4	$1.6M	Buy	121,640 +90,950	+296%	+$1.07M	﹤0.01%	2212
2025 Q3	$220K	Buy	30,690 +13,119	+75%	+$684K	﹤0.01%	3881
2025 Q2	$829K	Buy	17,571 +629	+4%	+$25.6K	﹤0.01%	2828
2025 Q1	$662K	Buy	+16,942	New	+$730K	﹤0.01%	3033
2024 Q4	–	Sell	-6,402	Closed	-$327K	–	5332
2024 Q3	$323K	Sell	6,402 -938	-13%	-$44K	﹤0.01%	3394
2024 Q2	$323K	Buy	+7,340	New	+$311K	﹤0.01%	3388
2024 Q1	–	Sell	-18,903	Closed	-$1.14M	–	4370
2023 Q4	$1.14M	Buy	18,903 +4,994	+36%	+$257K	﹤0.01%	2429
2023 Q3	$793K	Sell	13,909 -27,522	-66%	-$1.52M	﹤0.01%	2481
2023 Q2	$2.11M	Buy	+41,431	New	+$1.11M	0.01%	1627

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Squarepoint's MLTX Position: Q2 2026 in Review

Squarepoint reduced its MoonLake Immunotherapeutics (MLTX) stake by 23% in Q2 2026, selling an estimated $454K and leaving 85,147 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2488.

Squarepoint first reported a position in MLTX in Q2 2023 and has held it in 11 quarters since. The position peaked at $2.11M in Q2 2023. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Squarepoint held 85,147 shares of MoonLake Immunotherapeutics worth $1.66M as of Q2 2026.
Squarepoint sold 25,070 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $454K.
MoonLake Immunotherapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2488 holding.
Squarepoint first reported a position in MoonLake Immunotherapeutics in Q2 2023 and has held it in 11 quarters since.
Squarepoint's MoonLake Immunotherapeutics position peaked at $2.11M in Q2 2023.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.